Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Nephrol Dial Transplant ; 19 Suppl 3: iii43-6, 2004 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-15192135

RESUMO

BACKGROUND: The last decade has witnessed a sustained improvement of renal allograft survival that is partly explained by a better preservation of renal allograft function. This study describes time-dependent modifications of serum creatinine (SCr) during the first year after transplantation in the last decade in Spain and characterizes the predictive value of SCr on death-censored graft survival. METHODS: A total of 3365 adult patients transplanted in 1990 (n = 824), 1994 (n = 1075) and 1998 (n = 1466) with a functioning graft after the first year were included. Renal function deterioration during the first year was expressed as the difference between SCr at 1 year and SCr at 3 months. RESULTS: Despite the projected renal allograft half-life, estimation was significantly higher in 1998 than in 1990 (17.7 vs 15.4 years, P = 0.007), the SCr levels at 3 months were significantly lower in 1990 (1.59+/-0.64) than in 1998 (1.65+/-0.66). While SCr tended to worsen during the first year in 1990 (0.05+/-0.64) it improved in 1998 (-0.003+/-0.48), P = 0.0001. The following variables were significantly associated with SCr at 3 months: donor age and sex, cause of death, recipient sex, time on dialysis, cold ischaemia time, delayed graft function, acute rejection, cytomegalovirus infection and reintervention for any reason. Renal function deterioration during the first year was associated with the presence of acute rejection and hepatitis C virus antibodies in the recipient. CONCLUSIONS: Despite poorer renal function at 3 months in 1998 than in 1990, renal allograft survival has improved in Spain between 1990 and 1998. This result is partly explained by a slower deterioration of renal function during the first year of follow-up.


Assuntos
Transplante de Rim/fisiologia , Feminino , Sobrevivência de Enxerto , Humanos , Masculino , Valor Preditivo dos Testes , Espanha , Fatores de Tempo
2.
Transplantation ; 77(2): 215-20, 2004 Jan 27.
Artigo em Inglês | MEDLINE | ID: mdl-14742984

RESUMO

BACKGROUND: Although studies have shown that mycophenolate mofetil (MMF) with cyclosporine (CsA) and prednisone can reduce the incidence of acute rejection and increase the half-life of the graft, the effects of MMF on established chronic allograft nephropathy (CAN) are controversial. METHODS: We studied 121 patients with biopsy-proven CAN, 59 treated with CsA and prednisone and 62 treated with triple-drug therapy with azathioprine. At inclusion, each group received 2 g per day of MMF and azathioprine was stopped. Renal function was measured by the glomerular filtration rate (GFR) obtained by creatinine clearance (Cockcroft-Gault) and monitored by the slope of the GFR, adjusted using linear regression. RESULTS: The median follow-up, after incorporation of MMF, was 36 (13-36) months, with 103 (85.1%) having a full 3-year follow-up. Before the introduction of MMF, there was progressive deterioration in renal function (GFR: 54.8+/-20.9 vs. 39.7+/-14.0 mL/min, P<0.001). After introduction of MMF, renal function remained stable (GFR: 39.7+/-14.0 vs. 41.3+/-10.8 mL/min, P=NS), with a significant change in the slope of the GFR (-0.0144 vs. +0.00045, P<0.001). In 65 patients in whom CsA blood levels remained unchanged during follow-up (148.0+/-65.6 vs. 154.1+/-58.2, P=NS), the slope of the GFR showed a reduction in loss of renal function (-0.0147 vs. -0.0001, P<0.001). CONCLUSIONS: Treatment with MMF reduced the progressive deterioration of renal function in patients with CAN, independently of the blood levels of CsA.


Assuntos
Taxa de Filtração Glomerular/efeitos dos fármacos , Transplante de Rim/imunologia , Transplante de Rim/patologia , Ácido Micofenólico/análogos & derivados , Ácido Micofenólico/uso terapêutico , Complicações Pós-Operatórias/imunologia , Adulto , Azatioprina/uso terapêutico , Creatinina/metabolismo , Ciclosporina/sangue , Ciclosporina/uso terapêutico , Feminino , Seguimentos , Teste de Histocompatibilidade , Humanos , Imunossupressores/sangue , Imunossupressores/uso terapêutico , Isoanticorpos/sangue , Testes de Função Renal , Masculino , Complicações Pós-Operatórias/prevenção & controle , Análise de Regressão , Fatores de Tempo
3.
Nephrol Dial Transplant ; 18(3): 603-6, 2003 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-12584286

RESUMO

BACKGROUND: Although hyperuricaemia and gout are frequently found in renal transplant recipients, little has been published on the efficacy of urate-lowering therapy (ULT) in this patient population. We therefore examine the effects of allopurinol and benziodarone therapy in a cohort of renal transplant patients. METHODS: We reviewed files from a cohort of 1328 patients that received renal transplantation. The selection criteria included: functioning allograft, hyperuricaemia for >12 months or gout, ULT lasting at least 1 year and at least two control measurements after the onset of ULT. Patients on azathioprine were treated with benziodarone to avoid azathioprine-allopurinol interactions. RESULTS: Two-hundred and seventy-nine patients fulfilled the criteria for review. They were treated with 289 courses of ULT: 100 with allopurinol (mean dose: 376 mg/day/dl/min of creatinine clearance) and 189 with benziodarone (mean dose: 73 mg/day). The mean follow-up was 38 months. Both drugs were effective for the control of hyperuricaemia, but benziodarone caused greater reductions in serum uric acid levels, especially when used at mean doses of >75 mg/day. Severe side effects were uncommon, in both the allopurinol and benziodarone groups. CONCLUSIONS: Both allopurinol and benziodarone were effective for the control of hyperuricaemia in renal transplantation. Benziodarone at doses >75 mg/day was more effective than allopurinol in reducing serum uric acid levels and also reduced the risk of azathioprine-allopurinol interactions.


Assuntos
Alopurinol/uso terapêutico , Antimetabólitos/uso terapêutico , Azatioprina/uso terapêutico , Hiperuricemia/tratamento farmacológico , Hiperuricemia/etiologia , Falência Renal Crônica/cirurgia , Transplante de Rim/efeitos adversos , Adolescente , Adulto , Idoso , Criança , Estudos de Coortes , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Fatores de Tempo
4.
Int J Dermatol ; 42(1): 18-22, 2003 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-12581135

RESUMO

BACKGROUND: Kaposi's sarcoma (KS) in renal transplant recipients (RTRs) probably arises from a complex interplay of multiple factors. OBJECTIVE: In order to analyze the prevalence of KS in patients transplanted at the Cruces Hospital in Bilbao, together with their clinical features, treatment, and etiologic factors, we performed a study using the registry of RTRs in our center. METHODS: The records of 1,230 kidney transplant patients at the Cruces Hospital between 1979 and 1998 were reviewed. Immunosuppressive therapy was reduced once a diagnosis of KS was made. A nested polymerase chain reaction was used to detect human herpesvirus 8 (HHV-8) DNA in the biopsy tissue. The DNA was extracted from fresh tissue (n = 2) or from formalin-fixed, paraffin-embedded specimens (n = 5). RESULTS: Six cases of KS were diagnosed. All patients with cutaneous KS improved with a reduction in immunosuppressive drugs. HHV-8 was detected in 100% (2/2) of the frozen biopsies and 20% (1/5) of the formalin-fixed samples investigated. CONCLUSIONS: Our experience indicates that a continuous state of immunodeficiency is important for the development of KS in RTRs. The association, previously described between HHV-8 and transplant-associated KS, also exists in the studied population.


Assuntos
DNA Viral/análise , Falência Renal Crônica/epidemiologia , Falência Renal Crônica/cirurgia , Transplante de Rim/estatística & dados numéricos , Sarcoma de Kaposi/epidemiologia , Neoplasias Cutâneas/epidemiologia , Idoso , Biópsia por Agulha , Comorbidade , Feminino , Rejeição de Enxerto , Sobrevivência de Enxerto , Herpesvirus Humano 6/isolamento & purificação , Herpesvirus Humano 8/isolamento & purificação , Hospitais Urbanos , Humanos , Imunossupressores/uso terapêutico , Masculino , Pessoa de Meia-Idade , Reação em Cadeia da Polimerase , Prevalência , Prognóstico , Sistema de Registros , Estudos Retrospectivos , Medição de Risco , Fatores de Risco , Sarcoma de Kaposi/diagnóstico , Sarcoma de Kaposi/tratamento farmacológico , Neoplasias Cutâneas/diagnóstico , Neoplasias Cutâneas/tratamento farmacológico , Espanha/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...